International Stem Cell CORP
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 9745 BUSINESSPARK AVENUE, SAN DIEGO, CA, 92131
Mailing Address 9745 BUSINESSPARK AVENUE, SAN DIEGO, CA, 92131
Phone 760-940-6383
Fiscal Year End 1231
EIN 204494098
Financial Overview
FY2025
-$209K
Net Income
$4.80M
Total Liabilities
$-0.03
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | November 18, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | September 16, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
| 4 Insider stock transaction report | June 20, 2025 | View on SEC |
| 4 Insider stock transaction report | June 20, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 14, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | April 24, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Successful Phase 1 clinical trial for Parkinson’s treatment with promising safety and efficacy data.
- Proprietary stem cell technology (hpSCs) offers a unique alternative to embryonic stem cells.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.